Obesity Clinical Trial
Official title:
The Influence of the Provision of a To-go Container on the Portion Size Effect in Women
Verified date | April 2018 |
Source | Penn State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study investigated whether the provision of a to-go container influenced the portion size effect at a meal. Following a screening visit, women came to the lab once a week for 4 weeks to eat a meal of multiple foods. At each visit, the portion size of the meal was varied in a counterbalanced order. Prior to their first meal, women were randomly assigned to one of two groups: a group that would have their leftovers packaged to go (to-go group) and a group that did not have leftovers packaged (control group). Women were instructed to eat ad libitum at the meals. They also answered questions about hunger and fullness as well as food characteristics before and after each meal. Following the final meal, subjects completed a series of questionnaires assessing subject characteristics as well as food characteristics. It was hypothesized that the effect of portion size on intake would be attenuated in subjects who received a to-go container with the meal. In addition, we aimed to identify any subject characteristics that moderated or exacerbated the portion size effect. It was also of interest to determine whether the portion size effect on individual foods were influenced by food characteristics such as perceived value.
Status | Completed |
Enrollment | 58 |
Est. completion date | December 2017 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Regularly eats 3 meals/day - Willing to avoid alcohol the day before and during test days - Likes foods offered at test meals - Body mass index 18 - 36 (kg/m*m) Exclusion Criteria: - Smokes - Athlete in training - Pregnant or breastfeeding - Taking medication that may affect appetite or food intake - Food allergies or dietary restrictions - Currently have or recently been diagnosed with disease or disorder known to affect appetite |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Penn State University | Jenny Craig, Inc., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), United States Department of Agriculture (USDA) |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the weight of food consumed | Change in the weight of food consumed (in grams) across experimental conditions and intervention groups. | Weeks 1, 2, 3, and 4 | |
Primary | Change in energy intake | Change in energy intake (in kcal) across experimental conditions and intervention groups. | Weeks 1, 2, 3, and 4 | |
Secondary | Change in energy density consumed | Change in food energy density consumed (in kcal/g) across experimental conditions and intervention groups. | Weeks 1, 2, 3, and 4 | |
Secondary | Change in intake of individual foods | Change in both the weight (g) and energy (kcal) consumed of individual foods served at the meal across experimental conditions and intervention groups. | Weeks 1, 2, 3, and 4 | |
Secondary | Changes in post-meal measures of satiety | Changes in post-meal measures of satiety across experimental conditions and intervention groups using 100-mm visual analog scales. | Weeks 1, 2, 3, and 4 | |
Secondary | Changes in post-meal ratings of meal characteristics | Changes in post-meal ratings of meal characteristics across experimental conditions and between subject groups using 100-mm visual analog scales. | Weeks 1, 2, 3, and 4 | |
Secondary | Changes in ratings of food properties | Changes in post-meal ratings of food properties across experimental conditions and subject groups using 100-mm visual analog scales. | Weeks 1, 2, 3, and 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |